Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys

[1]  M. Michalopoulou,et al.  Serum Levels of Soluble Intercellular Adhesion Molecule-1 and Soluble Endothelial Leukocyte Adhesion Molecule-1 in Alzheimer’s Disease , 2004, Journal of geriatric psychiatry and neurology.

[2]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[3]  A. Gasbarrini,et al.  Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  E. Hirsch,et al.  Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure , 2004, Glia.

[5]  P. Mcgeer,et al.  Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.

[6]  Jianping Li,et al.  Polymorphism K469E of intercellular adhesion molecule-1 gene and restenosis after coronary stenting in Chinese patients. , 2004, Chinese medical journal.

[7]  P. Bingley,et al.  Association of intercellular adhesion molecule-1 gene with type 1 diabetes , 2003, The Lancet.

[8]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[9]  A. Krętowski,et al.  Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  B. Engelhardt,et al.  Intracellular Domain of Brain Endothelial Intercellular Adhesion Molecule-1 Is Essential for T Lymphocyte-Mediated Signaling and Migration1 , 2003, The Journal of Immunology.

[11]  B. Liu,et al.  Novel anti-inflammatory therapy for Parkinson's disease. , 2003, Trends in pharmacological sciences.

[12]  W. Willett,et al.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.

[13]  R. Flore,et al.  Synergistic Effect of −174 G/C Polymorphism of the Interleukin-6 Gene Promoter and 469 E/K Polymorphism of the Intercellular Adhesion Molecule-1 Gene in Italian Patients With History of Ischemic Stroke , 2003, Stroke.

[14]  R. Bernabei,et al.  Intercellular adhesion molecule-1 K469E gene polymorphism and Alzheimer’s disease , 2003, Neurobiology of Aging.

[15]  J. Ilonen,et al.  Intercellular adhesion molecule-1 K469E polymorphism: study of association with multiple sclerosis. , 2003, Human immunology.

[16]  H. Asakura,et al.  Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population , 2003, Gut.

[17]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[18]  D. Niederacher,et al.  C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, codon 469). A risk factor for coronary heart disease and myocardial infarction. , 2002, International journal of cardiology.

[19]  R. Bernabei,et al.  Association between intercellular adhesion molecule-1 E/K gene polymorphism and probable vascular dementia in humans , 2002, Neuroscience Letters.

[20]  R. Krüger,et al.  Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease , 2002, Neuroscience Letters.

[21]  P. Mcgeer,et al.  Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease , 2002, Neuroscience Letters.

[22]  D. Tanné,et al.  Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. , 2002, Journal of the American College of Cardiology.

[23]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[24]  I. Olivieri,et al.  Intercellular adhesion molecule-1 gene polymorphisms in Behçet's Disease. , 2001, The Journal of rheumatology.

[25]  T. Quirico-Santos,et al.  Determination of soluble ICAM-1 and TNFalphaR in the cerebrospinal fluid and serum levels in a population of Brazilian patients with relapsing-remitting multiple sclerosis. , 2001, Arquivos de neuro-psiquiatria.

[26]  M. Yacoub,et al.  Identification of ICAM-1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. , 2001, Human immunology.

[27]  E. Benveniste,et al.  ICAM-1-Induced Expression of Proinflammatory Cytokines in Astrocytes: Involvement of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways1 , 2000, The Journal of Immunology.

[28]  C. Salvarani,et al.  Intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in Italian patients with rheumatoid arthritis. , 2000, Clinical and experimental rheumatology.

[29]  E. Hirsch.  Glial cells and Parkinson’s disease , 2000, Journal of Neurology.

[30]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[31]  C. Massart,et al.  Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves’ disease , 1999, Journal of endocrinological investigation.

[32]  B. Müller-Myhsok,et al.  A susceptibility locus for Parkinson's disease maps to chromosome 2p13 , 1998, Nature Genetics.

[33]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[34]  L. Davis,et al.  Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. , 1994, Arthritis and rheumatism.

[35]  T. L. Collins,et al.  Adhesion receptors in lymphocyte activation. , 1994, Current opinion in immunology.

[36]  P. Rieckmann,et al.  Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: An indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier , 1993, Journal of Neuroimmunology.

[37]  Timothy A. Springer,et al.  Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation , 1991, Cell.

[38]  D. Tenen,et al.  Point mutations impairing cell surface expression of the common beta subunit (CD18) in a patient with leukocyte adhesion molecule (Leu-CAM) deficiency. , 1990, The Journal of clinical investigation.

[39]  P. Mcgeer,et al.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.

[40]  R. Rothlein,et al.  Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. , 1988, Journal of immunology.

[41]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[42]  T. Springer,et al.  ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells , 1988, Nature.

[43]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[44]  T. Springer,et al.  Heterogeneous mutations in the β subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency , 1987, Cell.

[45]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.

[46]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[47]  I. Tooyama,et al.  Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders , 2004, Acta Neuropathologica.

[48]  P. Mcgeer,et al.  Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.

[49]  Ashley Harms.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[50]  H. Ichinose,et al.  Cytokines in Parkinson’s Disease , 2000 .

[51]  K. Kugiyama,et al.  Plasma soluble intercellular adhesion molecule-1 levels in coronary circulation in patients with unstable angina. , 1999, The American journal of cardiology.